Skip to main content
. 2020 Jun 4;52(2):351–358. doi: 10.1111/apt.15836

TABLE 3.

Adverse events attributed to vasoconstrictor treatment

Terlipressin

(N = 203)

Other vasopressors

(N = 22)

Any, N (%) 50 (25) 9 (41)
Fluid overload or pulmonary oedema 32 (16) 7 (32)
Mesenteric ischemia 3 (2) 0 (0)
Multi‐organ failure 18 (9) 2 (9)
Myocardial infarction 2 (1) 0 (0)

Adverse events were attributed to therapy by the treating clinician.

Abbreviation: N, number.